NCT07139522 Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia
| NCT ID | NCT07139522 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Dexamethasone |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2023-12-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the efficacy of adding dexamethasone and magnesium sulfate as an adjuvant to bupivacaine in bilateral erector spinae block in postoperative pain control in patients undergoing caesarean section under spinal anesthesia.
Eligibility Criteria
Inclusion Criteria: * Age from 18 to 35 years. * Full-term, singleton, pregnant women. * American Society of Anesthesiologists (ASA) physical status II. * Scheduled for elective cesarean delivery under spinal anesthesia. Exclusion Criteria: * Refusal of the patient. * Emergency caesarean sections. * Patients having chronic diseases as asthma, cardiovascular disorders (Significant arrhythmias, Severe Valvular diseases, congenital heart diseases, ischemic heart disease, cardiomyopathy, deep venous thrombosis ,and pulmonary embolism) * Renal impairment (Creatinine level ≥ 2mg/dl, urea ≥ 25mg/dL), liver impairment \[Alanine aminotransferase (ALT) \< 45 U/L, Aspartate aminotransferase (AST) \< 45 U/L\]. * Allergy to the drug enrolled in the study. * Body mass index (BMI) ≥ 35 kg/m2. * Hypertensive disorders of pregnancy. * Contraindication to spinal anesthesia, such as coagulopathy \[platelet count \<150.000, international normalized ratio (INR) \> 1.2\], or local infection. * Requirement for conversion to general anesthesia after spinal anesthesia will also be excluded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07139522 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Dexamethasone. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07139522 currently recruiting?
Yes, NCT07139522 is actively recruiting participants. Contact the research team at esraa.es1@gmail.com for enrollment information.
Where is the NCT07139522 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07139522 clinical trial?
NCT07139522 is sponsored by Cairo University. The trial plans to enroll 150 participants.